Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort Study
Introduction: Most patients with pancreatic cancer experience systemic recurrence within 1 to 2 years after radical pancreatectomy. Phellinus linteus (PL) has demonstrated anti-inflammatory, antioxidant, and anti-cancer properties, suggesting potential as an adjunct to cancer therapy. This study aim...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Integrative Cancer Therapies |
| Online Access: | https://doi.org/10.1177/15347354251353499 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849707150646968320 |
|---|---|
| author | Juwan Kim MD Seung Soo Hong MD Sung Hyun Kim MD, MS Ho Kyoung Hwang MD, PhD Chang Moo Kang MD, PhD |
| author_facet | Juwan Kim MD Seung Soo Hong MD Sung Hyun Kim MD, MS Ho Kyoung Hwang MD, PhD Chang Moo Kang MD, PhD |
| author_sort | Juwan Kim MD |
| collection | DOAJ |
| description | Introduction: Most patients with pancreatic cancer experience systemic recurrence within 1 to 2 years after radical pancreatectomy. Phellinus linteus (PL) has demonstrated anti-inflammatory, antioxidant, and anti-cancer properties, suggesting potential as an adjunct to cancer therapy. This study aimed to evaluate the long-term oncological impact of perioperative PL in resected pancreatic cancer. Method: This retrospective cohort study included 407 patients who underwent curative resection and adjuvant chemotherapy for pancreatic cancer at Severance Hospital (2012-2022). Among them, 103 patients who began PL postoperatively and continued throughout treatment were assigned to the PL group; 304 patients without PL intake comprised the control group. Results: The mean overall survival (OS) was significantly longer in the PL group (47.0 months; 95% CI: 42.8-51.1) than in the control group (35.0 months; 95% CI: 30.3-39.7; P < .001). Recurrence-free survival (RFS) showed a borderline improvement ( P = .053). PL use was marginally associated with improved OS in multivariate analysis (HR: 0.614; 95% CI: 0.376-1.002; P = .051). Subgroup analysis showed no significant OS or RFS benefit with PL in patients receiving FOLFIRINOX. However, among patients treated with non-FOLFIRINOX regimens, PL use led to significantly better OS (43.9 months vs 35.0 months; P = .021), though RFS remained similar. Notably, the OS of the non-FOLFIRINOX + PL group was comparable to that of the FOLFIRINOX group ( P = .332) and superior to the non-FOLFIRINOX control group ( P = .021). Conclusion: PL may enhance survival in resected pancreatic cancer, particularly in patients receiving non-FOLFIRINOX chemotherapy, supporting its role as a potential adjunct when FOLFIRINOX is not feasible. |
| format | Article |
| id | doaj-art-eedc499abefb471f907c036fd78d2f83 |
| institution | DOAJ |
| issn | 1552-695X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Integrative Cancer Therapies |
| spelling | doaj-art-eedc499abefb471f907c036fd78d2f832025-08-20T03:16:00ZengSAGE PublishingIntegrative Cancer Therapies1552-695X2025-06-012410.1177/15347354251353499Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort StudyJuwan Kim MD0Seung Soo Hong MD1Sung Hyun Kim MD, MS2Ho Kyoung Hwang MD, PhD3Chang Moo Kang MD, PhD4Yonsei Cancer Center, Severance Hospital, Seoul, KoreaYonsei Cancer Center, Severance Hospital, Seoul, KoreaYonsei Cancer Center, Severance Hospital, Seoul, KoreaYonsei Cancer Center, Severance Hospital, Seoul, KoreaYonsei Cancer Center, Severance Hospital, Seoul, KoreaIntroduction: Most patients with pancreatic cancer experience systemic recurrence within 1 to 2 years after radical pancreatectomy. Phellinus linteus (PL) has demonstrated anti-inflammatory, antioxidant, and anti-cancer properties, suggesting potential as an adjunct to cancer therapy. This study aimed to evaluate the long-term oncological impact of perioperative PL in resected pancreatic cancer. Method: This retrospective cohort study included 407 patients who underwent curative resection and adjuvant chemotherapy for pancreatic cancer at Severance Hospital (2012-2022). Among them, 103 patients who began PL postoperatively and continued throughout treatment were assigned to the PL group; 304 patients without PL intake comprised the control group. Results: The mean overall survival (OS) was significantly longer in the PL group (47.0 months; 95% CI: 42.8-51.1) than in the control group (35.0 months; 95% CI: 30.3-39.7; P < .001). Recurrence-free survival (RFS) showed a borderline improvement ( P = .053). PL use was marginally associated with improved OS in multivariate analysis (HR: 0.614; 95% CI: 0.376-1.002; P = .051). Subgroup analysis showed no significant OS or RFS benefit with PL in patients receiving FOLFIRINOX. However, among patients treated with non-FOLFIRINOX regimens, PL use led to significantly better OS (43.9 months vs 35.0 months; P = .021), though RFS remained similar. Notably, the OS of the non-FOLFIRINOX + PL group was comparable to that of the FOLFIRINOX group ( P = .332) and superior to the non-FOLFIRINOX control group ( P = .021). Conclusion: PL may enhance survival in resected pancreatic cancer, particularly in patients receiving non-FOLFIRINOX chemotherapy, supporting its role as a potential adjunct when FOLFIRINOX is not feasible.https://doi.org/10.1177/15347354251353499 |
| spellingShingle | Juwan Kim MD Seung Soo Hong MD Sung Hyun Kim MD, MS Ho Kyoung Hwang MD, PhD Chang Moo Kang MD, PhD Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort Study Integrative Cancer Therapies |
| title | Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort Study |
| title_full | Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort Study |
| title_fullStr | Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort Study |
| title_full_unstemmed | Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort Study |
| title_short | Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort Study |
| title_sort | perioperative clinical usage of phellinus linteus as a nutraceutical for non folfirinox based postoperative adjuvant chemotherapy for resected pancreatic cancer a retrospective cohort study |
| url | https://doi.org/10.1177/15347354251353499 |
| work_keys_str_mv | AT juwankimmd perioperativeclinicalusageofphellinuslinteusasanutraceuticalfornonfolfirinoxbasedpostoperativeadjuvantchemotherapyforresectedpancreaticcanceraretrospectivecohortstudy AT seungsoohongmd perioperativeclinicalusageofphellinuslinteusasanutraceuticalfornonfolfirinoxbasedpostoperativeadjuvantchemotherapyforresectedpancreaticcanceraretrospectivecohortstudy AT sunghyunkimmdms perioperativeclinicalusageofphellinuslinteusasanutraceuticalfornonfolfirinoxbasedpostoperativeadjuvantchemotherapyforresectedpancreaticcanceraretrospectivecohortstudy AT hokyounghwangmdphd perioperativeclinicalusageofphellinuslinteusasanutraceuticalfornonfolfirinoxbasedpostoperativeadjuvantchemotherapyforresectedpancreaticcanceraretrospectivecohortstudy AT changmookangmdphd perioperativeclinicalusageofphellinuslinteusasanutraceuticalfornonfolfirinoxbasedpostoperativeadjuvantchemotherapyforresectedpancreaticcanceraretrospectivecohortstudy |